



16424

2700-1-001N

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): David Nanus

SERIAL NO.: 09/811,346

EXAMINER: Karen A. Canella

DATE FILED: March 16, 2001

ART UNIT: 1642

FOR: COMBINED INTERFERON ALPHA AND LIPSOSOMAL-
ENCAPSULATED ALL-TRANS RETINOIC ACID, INCLUDING
PREPARATION AND USE

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450 on June 13, 2003.

Betty Schultz
(Name of depositor)

Betty Schultz 6/13/03
(Signature and Date)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

JUN 18 2003

TECH CENTER 1600/2900

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References AT through CK listed on the attached Form PTO-1449.


06/17/2003 NHOHAMM1 00000073 09811346

01 FC:1806

180.00 OP

Since this Information Disclosure Statement is filed after mailing of the first office action but prior to mailing of a final office action or notice of allowance, a check in the amount of \$180.00 is included to cover the fee due pertinent to C.F.R. 37 §1.97(c). Please charge any additional fees, or credit any overpayments, to Klauber & Jackson Deposit Account 11-1153.


Respectfully submitted,



David A. Jackson
Attorney for Applicants
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800

Date: June 13, 2003



Sheet 1 of 3

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2700-1-001N
	SERIAL NO.	09/811,346
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	David Nanus
	FILING DATE	March 16, 2001
	GROUP	1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

RECEIVED

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

JUN 18 2003

ECH CENTER 1600/2900

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	AT	Adamson et al., J Clin Oncol., 15:3330-7 (1997)
✓	AU	Arbaje et al., Journal of Interferon Research, 13:25-32 (1993)
✓	AV	Arnold et al., J Natl Cancer Inst., 86:306-9 (1994)
✓	AW	Athanasiadis et al., Clin Cancer Res., 1:973-9 (1995)
✓	AX	Atzpodien et al., World J Urol, 13:174-177 (1995)
✓	AY	Bollag et al., in <u>Retinoids in Oncology</u> , W.K. Hong and R. Lotan (eds), Chapter 4, pages 89-108 (1993)
✓	AZ	Bonhomme-Faivre et al., International Journal of Pharmaceutics, 134:99-104 (1996)
✓	BA	Brembeck et al., Cancer, 83:2317-23 (1998)
✓	BB	Casali et al., J Exp Clin Cancer Res., 17:227-9 (1998)
✓	BC	Cascinu et al., Ann Oncol., 7:538-9 (1996)

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2700-1-001N
	SERIAL NO.	09/811,346
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	David Nanus
	FILING DATE	March 16, 2001
	GROUP	1642

✓	BD	Dhingra et al., Invest New Drugs, 11:39-43 (1993)
✓	BE	Eisenhauer et al., Leukemia, 8:1622-5 (1994)
✓	BF	Escudier et al., J Immunother, 21:62-4 (1998)
✓	BG	Fierlbeck et al., Cancer Immunol Immunother., 40:157-64 (1995)
✓	BH	Frey et al., Cancer Letters, 57:223-227 (1991)
✓	BI	Hallum et al., Gynecol Oncol., 56:382-6 (1995)
✓	BJ	Handa et al., Leukemia Res., 21:1087-96 (1997)
✓	BK	Hoffmann et al., Int J Cancer, 70:475-7 (1997)
✓	BK	Knobler et al., J Am Acad Dermatol, 24:247-52 (1991)
✓	BL	Kok et al., Eur J Cancer, 33:165-6 (1997)
✓	BM	Kudelka et al., Anti-Cancer Drugs, 4:335-7 (1993)
✓	BN	Lindner et al., Clin Cancer Res., 3:931-7 (1997)
✓	BO	Lingen et al., Cancer Res., 58:5551-8 (1998)
✓	BP	Lippman et al., J Natl Cancer Inst., 85:499-500 (1993)
✓	BQ	Lippman et al., J Natl Cancer Inst., 84:235-241 (1992)
✓	BR	Lippman et al., J Natl Cancer Inst., 84:241-245 (1992)
✓	BS	Marth et al., JNCL, 77:1197-1202 (1986)
✓	BT	Matarrese et al., Int. J. Cancer, 76:531-40 (1998)

RECEIVED

JUN 18 2003

TECH CENTER 1600/2900

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Sheet 3 of 3

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2700-1-001N
	SERIAL NO.	09/811,346
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	David Nanus
	FILING DATE	March 16, 2001
	GROUP	1642

✓	BU	Moore et al., Semin Hematol., 31(4, Suppl 5):31-7 (1994)
✓	BV	Moore et al., Am J Clin Oncol., 18:525-7 (1995)
✓	BW	Nikolaou et al., J Laryngol Otol., 110:857-61 (1996)
✓	BX	Pazdur et al., Am J Clin Oncol., 18:436-8 (1995)
✓	BY	Rinaldi et al., Anti-Cancer Drugs, 4:33-6 (1993)
✓	BZ	Rosenthal et al., Am J Clin Oncol., 21:352-4 (1998)
✓	CA	Roth et al., Oncology, 51:84-6 (1994)
✓	CB	Slabber et al., Invest New Drugs., 14:391-4 (1996)
✓	CC	Sondak et al., Cancer J Sci Am., 5:41-7 (1999)
✓	CD	Spieth et al., Arch Derm, 135:1035-1037 (1999)
✓	CE	Toma et al., Int J Cancer, 70:491-3 (1997)
✓	CF	Toma et al., Ann Oncol., 5:463-5 (1994)
✓	CG	Toma et al., Anticancer Res., 16:931-6 (1996)
✓	CH	Trionzi et al., Cancer Invest., 14:293-8 (1996)
	CI	Voravud et al., Invest New Drugs, 11:57-60 (1993)
	CJ	Wadler et al., Cancer, 79:1574-1580 (1997)
	CK	Weiss et al., Gynecologic Oncology, 71:386-390 (1998)

RECEIVED

JUN 18 2003

TECH CENTER 1600/2900

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	